Stool simple

PreclinicalBiologic

HHospices Civils de Lyon

Stool simple is one of 2 biologic programs targeting SARS CoV 2 Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SARS Cov 2 InfectionCompleted

SARS Cov 2 InfectionPreclinical

Completed

Competition

Competitive Landscape

3 competitors in SARS Cov 2 Infection

#DrugCompanyPhaseTrials

Ibuzatrelvir

Pfizer

Phase 3

1 2

Stool simple

HHospices Civils de Lyon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Crohn's Disease1 trial

TOward a Better Understanding of the autoPhagy Machinery for the Identification of Potential Novel Biomarkers and Therapeutic Targets in Crohn's Disease - TOPIC Study

Not yet recruiting·HHospices Civils de Lyon·N/A·NCT06244849·170 enrolled

SARS CoV 2 Infection1 trial

Host-pathogen Interactions During SARS-CoV-2 Infection

Completed·HHospices Civils de Lyon·N/A·NCT04376476·140 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Stool simple. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Stool simple compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Stool simple. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospices Civils de Lyon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: HHospices Civils de Lyon

Stool simple

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Crohn's Disease1 trial

SARS CoV 2 Infection1 trial

References

Drug Info

Quick Facts

Related News